Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy.

Razzouk, Bassem I

Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Aug 2006 - 3583-9 p. digital

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1527-7755

10.1200/JCO.2005.03.4371 doi


Adolescent
Anemia, Hypochromic--drug therapy
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Bone Marrow--drug effects
Child
Child, Preschool
Double-Blind Method
Epoetin Alfa
Erythrocyte Transfusion
Erythropoietin--administration & dosage
Female
Health Status
Hematinics--administration & dosage
Hemoglobins--analysis
Humans
Male
Neoplasms--drug therapy
Quality of Life
Recombinant Proteins